apb-r3
Recombinant proteinexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 8, 2023 (NCT05715736)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-18INHIBITOR
IL18 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05715736 | Phase 1 | Mar 8, 2023 | AprilBio Co., Ltd., CMAX Clinical Research, Syneos Health |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AprilBio Co., Ltd. | For profit | 1 | 0 | 1 | 2023 |
| CMAX Clinical Research | For profit | 1 | 0 | 1 | 2023 |
| Syneos Health | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1